SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW
Scilex Holding Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.57−0.26 (-9.19%)
Close on Oct 19, 2026
- Market cap
- $17.71M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$10.21 (−79.89%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Scilex Holding Co saw revenue fall 28.5% to $31.61M over the twelve months to Jun 30, 2026. Free cash flow was $3.68M, down 81.0% from a year earlier.
Revenue
$31.61M
-28.5% vs. a year earlier
Operating income
-$359.19M
TTM Q2 2026
Free cash flow
$3.68M
-81.0% vs. a year earlier
EPS, diluted
-$36.48
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $17.71M
- P/E ratio
- –
- Price to sales
- 0.56
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 20.79%
Fundamentals
- Revenue
- $31.61M
- Net income
- -$464.56M
- EPS, diluted
- -$36.48
- Free cash flow
- $3.68M
- Book value per share
- -$44.74
- Diluted shares
- 7M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$31.61M-28.5% YoY
Gross profit
$50.91M-34.8% YoY
Operating income
-$359.19M
Net income
-$464.56M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months